ANI Pharmaceuticals (NASDAQ:ANIP) was upgraded by investment analysts at BidaskClub from a “hold” rating to a “buy” rating in a research report issued on Friday.

A number of other research analysts have also commented on ANIP. Canaccord Genuity set a $77.00 price target on shares of ANI Pharmaceuticals and gave the company a “buy” rating in a research note on Friday, December 29th. Zacks Investment Research lowered shares of ANI Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Tuesday. ValuEngine downgraded shares of ANI Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Wednesday, December 20th. Finally, TheStreet raised shares of ANI Pharmaceuticals from a “c+” rating to a “b” rating in a report on Thursday, November 16th. Three analysts have rated the stock with a hold rating and three have given a buy rating to the company. The company has an average rating of “Buy” and a consensus price target of $71.00.

Shares of ANI Pharmaceuticals (NASDAQ:ANIP) traded down $3.00 on Friday, reaching $69.41. 190,871 shares of the company were exchanged, compared to its average volume of 114,803. ANI Pharmaceuticals has a twelve month low of $42.23 and a twelve month high of $74.70. The firm has a market cap of $843.79, a price-to-earnings ratio of 108.45 and a beta of 2.90. The company has a debt-to-equity ratio of 0.83, a quick ratio of 2.39 and a current ratio of 3.45.

ANI Pharmaceuticals (NASDAQ:ANIP) last announced its quarterly earnings results on Thursday, November 2nd. The specialty pharmaceutical company reported $1.11 EPS for the quarter, beating the Zacks’ consensus estimate of $0.99 by $0.12. ANI Pharmaceuticals had a net margin of 4.45% and a return on equity of 22.40%. The business had revenue of $48.16 million for the quarter, compared to analyst estimates of $48.12 million. During the same quarter in the prior year, the business earned $1.09 EPS. ANI Pharmaceuticals’s quarterly revenue was up 25.0% on a year-over-year basis. analysts anticipate that ANI Pharmaceuticals will post 3.59 earnings per share for the current year.

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Thrivent Financial For Lutherans lifted its holdings in shares of ANI Pharmaceuticals by 7.1% during the 2nd quarter. Thrivent Financial For Lutherans now owns 4,840 shares of the specialty pharmaceutical company’s stock worth $227,000 after acquiring an additional 320 shares during the period. Ameriprise Financial Inc. lifted its holdings in shares of ANI Pharmaceuticals by 0.6% during the 2nd quarter. Ameriprise Financial Inc. now owns 54,205 shares of the specialty pharmaceutical company’s stock worth $2,536,000 after acquiring an additional 340 shares during the period. Dana Investment Advisors Inc. lifted its holdings in shares of ANI Pharmaceuticals by 0.8% during the 2nd quarter. Dana Investment Advisors Inc. now owns 42,720 shares of the specialty pharmaceutical company’s stock worth $1,999,000 after acquiring an additional 341 shares during the period. ETRADE Capital Management LLC lifted its holdings in shares of ANI Pharmaceuticals by 5.2% during the 2nd quarter. ETRADE Capital Management LLC now owns 12,990 shares of the specialty pharmaceutical company’s stock worth $608,000 after acquiring an additional 640 shares during the period. Finally, BNP Paribas Arbitrage SA lifted its holdings in shares of ANI Pharmaceuticals by 44.6% during the 2nd quarter. BNP Paribas Arbitrage SA now owns 2,152 shares of the specialty pharmaceutical company’s stock worth $101,000 after acquiring an additional 664 shares during the period. 55.05% of the stock is owned by hedge funds and other institutional investors.

ILLEGAL ACTIVITY NOTICE: This piece of content was originally posted by American Banking News and is the sole property of of American Banking News. If you are reading this piece of content on another site, it was illegally stolen and reposted in violation of US & international copyright & trademark legislation. The original version of this piece of content can be viewed at https://www.americanbankingnews.com/2018/01/06/ani-pharmaceuticals-anip-stock-rating-upgraded-by-bidaskclub.html.

About ANI Pharmaceuticals

ANI Pharmaceuticals, Inc is an integrated specialty pharmaceutical company. The Company is engaged in developing, manufacturing and marketing branded and generic prescription pharmaceuticals. The Company focuses on areas, including controlled substances, anti-cancer (oncolytics), hormones and steroids, and complex formulations.

Receive News & Ratings for ANI Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ANI Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.